Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM R3008H KIT V559D KIT D579del KIT D820Y KIT A829P |
| Therapy | Olaparib + Ripretinib |
| Indication/Tumor Type | gastrointestinal stromal tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM R3008H KIT V559D KIT D579del KIT D820Y KIT A829P | gastrointestinal stromal tumor | predicted - sensitive | Olaparib + Ripretinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Lynparza (olaparib) and Qinlock (ripretinib) resulted in stable disease with a progression-free survival of 6.2 months in a patient with recurrent gastrointestinal stromal tumor harboring KIT V559D, D579del, D820Y, and A829P and ATM R3008H (PMID: 40700673; NCT0253467). | 40700673 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40700673) | Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors. | Full reference... |